 Ionis Pharmaceuticals broadly missed second-quarter expectations Tuesday but reiterated its 2022 outlook and IONS stock inched up. The post Ionis Pharma Extends Breakout; Biotech Restates Guide Despite Quarterly Miss appeared first on Investors Business Daily. 